China Approves First Neutralizing Antibody Therapy for Covid-19

China’s drug regulator approved emergency use of Brii Biosciences’ neutralizing antibody therapy for Covid-19, the agency said Wednesday, making it the first treatment of its type approved in the country.

BRII-196 and BRII-198 — monoclonal neutralizing antibodies derived from recovered Covid-19 patients — were approved to treat adults and minors ages 12–17 with mild Covid-19 and high risk of progressing to severe illness, the National Medical Products Administration said.